Seres Therapeutics Inc. plans to start selling its first FDA-approved product, a drug called Vowst made of bacterial spores derived from donated feces, this summer at $17,500 a course.

CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 ...

The Kotak unit reported a loss of $10 million and clocked a premium income of $91.35 million in 2021-22, when bigger rival HDFC Ergo garnered $1.66 billion.

MUMBAI, July 25 (Reuters) - U.S. insurer Chubb (CB.BN) is in talks to acquire a 49% stake in India's Kotak General Insurance and has become a more favoured suitor than Zurich Insurance Group (ZURN ...